A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of the Investigational M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine When Administered Intramuscularly on a 0,1-month Schedule to Adolescents and Adults
Latest Information Update: 17 Jul 2025
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Registrational; Therapeutic Use
Most Recent Events
- 16 May 2025 Status changed from recruiting to active, no longer recruiting.
- 19 Mar 2024 The protocol has been amendment to change in study Time Frame: Up to 49 Months with decreased in study population
- 19 Mar 2024 Planned number of patients changed from 26000 to 20000.